Key facts
- Polar Capital Holdings Plc filed SCHEDULE 13G/A for Enliven Therapeutics, Inc. Common Stock, $0.001 par value per share (ELVN).
- Disclosed ownership: 4.9%.
- Date of event: 31 Dec 2024.
Polar Capital Holdings Plc - 31 Dec 2024 SCHEDULE 13G/A Report for Enliven Therapeutics, Inc. Common Stock, $0.001 par value per share (ELVN)
- Filing Manager
- Polar Capital Holdings Plc
- Reporting Manager
- Polar Capital Holdings Plc
- Symbol
- ELVN
- Shares outstanding
- 48,868,466 shares
- Disclosed Ownership
- 2,389,668 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 09:17:09 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Key filing fact
Polar Capital Holdings Plc disclosed 4.9% ownership in Enliven Therapeutics, Inc. Common Stock, $0.001 par value per share (ELVN) on 31 Dec 2024.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 09:17.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (3)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Polar Capital Holdings Plc | 4.9% | 2,389,668 | 2,389,668 | 0 | /s/ Nicholas Farren | Nicholas Farren - Chief Operating Officer | |
| Polar Capital LLP | 4.9% | 2,389,668 | 2,389,668 | 0 | /s/ Nicholas Farren | Nicholas Farren - Chief Operating Officer | |
| Polar Capital Funds PLC - Biotechnology Fund | 4.9% | 2,389,668 | 2,389,668 | 0 | /s/ Nicholas Farren | Nicholas Farren - Chief Operating Officer |
CIK / CUSIP context first